

Moglie Le Quintrec

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/11603997/publications.pdf>

Version: 2024-02-01

41
papers

3,926
citations

218677

26
h-index

265206

42
g-index

44
all docs

44
docs citations

44
times ranked

3704
citing authors

#	ARTICLE	IF	CITATIONS
1	Incisional hernia repair after kidney transplantation in a tertiary high-volume center: outcomes from a 10-year retrospective cohort study. <i>International Urology and Nephrology</i> , 2022, 54, 525-531.	1.4	3
2	IgG3 donor-specific antibodies with a proinflammatory glycosylation profile may be associated with the risk of antibody-mediated rejection after kidney transplantation. <i>American Journal of Transplantation</i> , 2022, 22, 865-875.	4.7	6
3	Eculizumab discontinuation in children and adults with atypical hemolytic-uremic syndrome: a prospective multicenter study. <i>Blood</i> , 2021, 137, 2438-2449.	1.4	87
4	Spectrum of Kidney Involvement in Patients with Myelodysplastic Syndromes. <i>Kidney International Reports</i> , 2021, 6, 746-754.	0.8	8
5	Clinical Utility of Biochemical Markers for the Prediction of COVID-19-Related Mortality in Kidney Transplant Recipients. <i>Kidney International Reports</i> , 2021, 6, 2689-2693.	0.8	8
6	Long-term health-related quality of life outcomes of adults with pediatric onset of frequently relapsing or steroid-dependent nephrotic syndrome. <i>Journal of Nephrology</i> , 2021, , 1.	2.0	2
7	The COVID-19 Pandemic Led to a Small Increase in Changed Mentality Regarding Infection Risk without Any Change in Willingness to Be Vaccinated in Chronic Diseases Patients. <i>Journal of Clinical Medicine</i> , 2021, 10, 3967.	2.4	6
8	Contactin-1 is a novel target antigen in membranous nephropathy associated with chronic inflammatory demyelinating polyneuropathy. <i>Kidney International</i> , 2021, 100, 1240-1249.	5.2	51
9	Combined Liver-Kidney Transplantation With Preformed Anti-human Leukocyte Antigen Donor-Specific Antibodies. <i>Kidney International Reports</i> , 2020, 5, 2202-2211.	0.8	6
10	An initial report from the French SOT COVID Registry suggests high mortality due to COVID-19 in recipients of kidney transplants. <i>Kidney International</i> , 2020, 98, 1549-1558.	5.2	213
11	Dynapaenia and sarcopaenia in chronic haemodialysis patients: do muscle weakness and atrophy similarly influence poor outcome?. <i>Nephrology Dialysis Transplantation</i> , 2020, 36, 1908-1918.	0.7	21
12	IMPact of the COVID-19 epidemic on the moRTality of kidney transplant recipients and candidates in a French Nationwide registry sTudy (IMPORTANT). <i>Kidney International</i> , 2020, 98, 1568-1577.	5.2	85
13	Distribution of de novo Donor-Specific Antibody Subclasses Quantified by Mass Spectrometry: High IgG3 Proportion Is Associated With Antibody-Mediated Rejection Occurrence and Severity. <i>Frontiers in Immunology</i> , 2020, 11, 919.	4.8	13
14	The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment. <i>Kidney International</i> , 2020, 97, 1287-1296.	5.2	123
15	Practical management of C3 glomerulopathy and Ig-mediated MPGN: facts and uncertainties. <i>Kidney International</i> , 2020, 98, 1135-1148.	5.2	28
16	Estimation of residual renal function using beta-trace protein: Impact of dialysis procedures. <i>Artificial Organs</i> , 2020, 44, 647-654.	1.9	1
17	Atypical and secondary hemolytic uremic syndromes have a distinct presentation and a common genetic risk factors. <i>Kidney International</i> , 2019, 95, 1443-1452.	5.2	74
18	C5b9 Deposition in Glomerular Capillaries Is Associated With Poor Kidney Allograft Survival in Antibody-Mediated Rejection. <i>Frontiers in Immunology</i> , 2019, 10, 235.	4.8	14

#	ARTICLE	IF	CITATIONS
19	Use of Highly Individualized Complement Blockade Has Revolutionized Clinical Outcomes after Kidney Transplantation and Renal Epidemiology of Atypical Hemolytic Uremic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2019, 30, 2449-2463.	6.1	81
20	Endothelium structure and function in kidney health and disease. <i>Nature Reviews Nephrology</i> , 2019, 15, 87-108.	9.6	292
21	Eculizumab reversed severe distal ischemic syndrome and glomerulonephritis with isolated C3 deposits associated with anti-factor H autoantibodies: a case report. <i>Clinical Rheumatology</i> , 2018, 37, 1119-1122.	2.2	0
22	Patterns of Clinical Response to Eculizumab in Patients With C3 Glomerulopathy. <i>American Journal of Kidney Diseases</i> , 2018, 72, 84-92.	1.9	94
23	In Reply to "Benefit of Eculizumab Compared to Standard of Care Still Unproven in C3 Glomerulopathy". <i>American Journal of Kidney Diseases</i> , 2018, 72, 906-907.	1.9	0
24	Both Monoclonal and Polyclonal Immunoglobulin Contingents Mediate Complement Activation in Monoclonal Gammopathy Associated-C3 Glomerulopathy. <i>Frontiers in Immunology</i> , 2018, 9, 2260.	4.8	42
25	Anti-Factor B and Anti-C3b Autoantibodies in C3 Glomerulopathy and Ig-Associated Membranoproliferative GN. <i>Journal of the American Society of Nephrology: JASN</i> , 2017, 28, 1603-1613.	6.1	83
26	Treatment of B-cell disorder improves renal outcome of patients with monoclonal gammopathy-associated C3 glomerulopathy. <i>Blood</i> , 2017, 129, 1437-1447.	1.4	120
27	C5 nephritic factors drive the biological phenotype of C3 glomerulopathies. <i>Kidney International</i> , 2017, 92, 1232-1241.	5.2	93
28	A novel CFHR1-CFHR5 hybrid leads to a familial dominant C3 glomerulopathy. <i>Kidney International</i> , 2017, 92, 876-887.	5.2	35
29	Stricturing Crohn's disease-like colitis in a patient treated with belatacept. <i>World Journal of Gastroenterology</i> , 2017, 23, 8660-8665.	3.3	5
30	Distinct roles for the complement regulators factor H and Crry in protection of the kidney from injury. <i>Kidney International</i> , 2016, 90, 109-122.	5.2	16
31	Targeting the complement cascade: novel treatments coming down the pike. <i>Kidney International</i> , 2016, 90, 746-752.	5.2	41
32	The Complement System and Antibody-Mediated Transplant Rejection. <i>Journal of Immunology</i> , 2015, 195, 5525-5531.	0.8	67
33	Eculizumab for Treatment of Rapidly Progressive C3 Glomerulopathy. <i>American Journal of Kidney Diseases</i> , 2015, 65, 484-489.	1.9	87
34	Anti-Factor H Autoantibodies in C3 Glomerulopathies and in Atypical Hemolytic Uremic Syndrome: One Target, Two Diseases. <i>Journal of Immunology</i> , 2015, 194, 5129-5138.	0.8	99
35	Spectrum of Complement-Mediated Thrombotic Microangiopathies: Pathogenetic Insights Identifying Novel Treatment Approaches. <i>Seminars in Thrombosis and Hemostasis</i> , 2014, 40, 444-464.	2.7	117
36	Targeted strategies in the prevention and management of atypical HUS recurrence after kidney transplantation. <i>Transplantation Reviews</i> , 2013, 27, 117-125.	2.9	74

#	ARTICLE	IF	CITATIONS
37	Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. <i>Nature Genetics</i> , 2013, 45, 531-536.	21.4	419
38	Genetics of hemolytic uremic syndromes. <i>Presse Medicale</i> , 2012, 41, e105-e114.	1.9	28
39	Acquired and genetic complement abnormalities play a critical role in dense deposit disease and other C3 glomerulopathies. <i>Kidney International</i> , 2012, 82, 454-464.	5.2	454
40	New insights into postrenal transplant hemolytic uremic syndrome. <i>Nature Reviews Nephrology</i> , 2011, 7, 23-35.	9.6	169
41	Clinical Features of Anti-Factor H Autoantibody-Associated Hemolytic Uremic Syndrome. <i>Journal of the American Society of Nephrology: JASN</i> , 2010, 21, 2180-2187.	6.1	247